ALLO Stock - Allogene Therapeutics, Inc.
Unlock GoAI Insights for ALLO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $22,000 | $95,000 | $156,000 | $114.09M | N/A |
| Gross Profit | $22,000 | $95,000 | $-14,139,000 | $114.09M | $-11,541,000 |
| Gross Margin | 100.0% | 100.0% | -9063.5% | 100.0% | N/A |
| Operating Income | $-273,199,000 | $-327,737,000 | $-335,536,000 | $-180,192,000 | $-258,243,000 |
| Net Income | $-257,590,000 | $-327,265,000 | $-340,414,000 | $-182,051,000 | $-250,221,000 |
| Net Margin | -1170863.6% | -344489.5% | -218214.1% | -159.6% | N/A |
| EPS | $-1.32 | $-2.09 | $-2.38 | $-1.34 | $-2.08 |
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 10th 2025 | JP Morgan | Downgrade | Underweight | - |
| May 14th 2025 | Citizens JMP | Downgrade | Market Perform | - |
| March 14th 2025 | Citizens JMP | Upgrade | Mkt Outperform | $5 |
| August 8th 2024 | Oppenheimer | Resumed | Outperform | $11← $13 |
| May 31st 2024 | Piper Sandler | Initiation | Overweight | $11 |
| January 5th 2024 | JMP Securities | Downgrade | Market Perform | - |
| January 5th 2024 | Guggenheim | Downgrade | Neutral | - |
| December 8th 2023 | Citigroup | Initiation | Buy | - |
| June 26th 2023 | Oppenheimer | Resumed | Outperform | $28 |
| March 21st 2023 | Bernstein | Initiation | Market Perform | $6 |
| January 24th 2023 | JP Morgan | Upgrade | Overweight | $11← $20 |
| January 6th 2023 | Robert W. Baird | Upgrade | Outperform | $12 |
| December 12th 2022 | BofA Securities | Downgrade | Underperform | $9← $24 |
| August 10th 2022 | Raymond James | Downgrade | Market Perform | - |
| July 15th 2022 | Goldman | Upgrade | Buy | $32← $9 |
Earnings History & Surprises
ALLOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $-0.25 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.23 | $-0.19 | +17.4% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.28 | $-0.23 | +17.9% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.28 | $-0.28 | 0.0% | = MET |
Q1 2025 | Mar 13, 2025 | $-0.34 | $-0.28 | +17.6% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.34 | $-0.27 | +20.6% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.35 | $-0.32 | +8.6% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.38 | $-0.38 | 0.0% | = MET |
Q1 2024 | Mar 14, 2024 | $-0.47 | $-0.43 | +8.5% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-0.53 | $-0.37 | +30.2% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $-0.59 | $-0.53 | +10.2% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.63 | $-0.68 | -7.9% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $-0.71 | $-0.66 | +7.0% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-0.62 | $-0.58 | +6.5% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.61 | $-0.52 | +14.8% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-0.59 | $-0.56 | +5.1% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $-0.61 | $-0.54 | +11.5% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-0.56 | $-0.57 | -1.8% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-0.55 | $-0.53 | +3.6% | ✓ BEAT |
Latest News
Allogene Therapeutics Reports Result for Servier In Arbitration With Cellectis; Arbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel; Decision Reconfirms Allogene's Expanded Sub-License Covering EU And UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights
📈 PositiveAllogene Therapeutics Q3 EPS $(0.19) Beats $(0.22) Estimate
📈 PositiveAllogene Therapeutics shares are trading lower after JP Morgan downgraded the stock from Neutral to Underweight.
📉 NegativeJP Morgan Downgrades Allogene Therapeutics to Underweight
📉 NegativeAllogene Therapeutics falls after trial delay, rating downgrade post Q1 results
📉 NegativeFrequently Asked Questions about ALLO
What is ALLO's current stock price?
What is the analyst price target for ALLO?
What sector is Allogene Therapeutics, Inc. in?
What is ALLO's market cap?
Does ALLO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ALLO for comparison